FEATURED EDITORIAL
Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.
- Novel Approach To Cancer Explores Severing Its Genetic Supply Line
- Target Transcription Factor States, Not Pockets
- Potency Is Not An Exposure Strategy
- Drugging The tRNA Control System
- Immune Reset In Rheumatology: Moving Beyond Disease Suppression Toward Durable Remission
- What The China Biotech Debate Reveals About U.S. Drug Discovery
- Closing The Loop Between AI And Experimental Biology
FEATURED APPLICATION CONTENT
-
Discover how high-throughput electroporation-based screening can compress your CAR-T optimization timeline while delivering reproducible, scale-ready results across multiple donor samples.
-
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.
-
Centralizing data unlocks faster insights, reduces duplicated effort, and improves compliance. By overcoming silos and “dark data,” organizations can enable efficient search, reuse, and analysis.
-
See how existing partnerships with NIH allowed the chance to bring together government, academic, and industry resources through strategic initiatives that streamline processes and maximize benefits.
-
See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.
-
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
-
Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
-
Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
-
Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.
-
Automated structure verification integrated into open-access NMR workflows cuts review time dramatically while maintaining confidence in results. See how smart parameter optimization improves efficiency.
- What The China Biotech Debate Reveals About U.S. Drug Discovery
- Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)
- Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit
- Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)
- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Artis BioSolutions Launches mRNA And Lipid Nanoparticle Manufacturing Capabilities At New 'Genetic Medicines Center Of Excellence' In Bilbao, Spain
- HepaRegeniX Receives Orphan Drug Designation For Darizmetinib For The Prevention Of Post-Hepatectomy Liver Failure
- ReviR Therapeutics Receives FDA Rare Pediatric Disease Designation For RTX-117 In Charcot-Marie-Tooth Disease
- SK Biopharmaceuticals To In-License Epilepsy Drug Candidate 'Opakalim'
- AI Drug Discovery Leaders Gain A Competitive Edge With Telesis Bio's Gibson SOLA Platform, Generating Development Candidates Faster
- U.S. FDA Approves Ziihera® (zanidatamab-hrii) With And Without Tislelizumab Plus Chemotherapy In First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
- Caliway's CBL-514 Combination Therapy Cleared By U.S. FDA For Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
- Vanda Pharmaceuticals Granted Orphan Designation For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis By The European Commission
- Insilico Medicine Convenes O3DC, An Open Consortium For Benchmark Quality In AI-Driven Drug Discovery
- GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval In India And Taiwan
ARCHIVED NEWSLETTER
- 08.27.26 -- Could These Assay & Screening Solutions Improve Your Workflow?
- 08.25.26 -- What The China Biotech Debate Reveals About U.S. Drug Discovery
- 08.20.26 -- Scaling Human-Relevant Science For Biologics Development
- 08.20.26 -- Target Discovery Solutions For Faster, Smarter R&D
- 08.19.26 -- Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)
